Paxlovid (nirmatrelvir-ritonavir) is efficient at stopping hospitalization and demise from COVID-19, however few individuals use it. A paper by SteelFisher et al. (2024) surveyed 1,430 American adults to search out out why. Their survey revealed sufferers had a lack of expertise of the therapy in addition to misinformation concerning the therapy (amongst those that have been conscious of it). Particularly:
A majority of respondents (85 p.c) had no or low consciousness of Paxlovid, together with 31 p.c who had by no means heard of it. Even amongst those that have been conscious of the drug, many held misperceptions about its effectiveness (39 p.c), adversarial results (86 p.c), and requisite timing (61 p.c) that might result in underuse. Decrease consciousness and misperceptions have been extra frequent amongst medically susceptible and deprived populations who may profit most from Paxlovid entry, together with adults unvaccinated in opposition to COVID-19, these with decrease ranges of schooling, and Black and Hispanic or Latino adults.
You may learn the complete paper right here.
